ERBB2 and breast cancer: Our patients showed higher TILs rate in all BC subgroups compared to women affected by BC without SSc as reported in literature, reaching a percentage of 25% in HR+/HER2 negative BC group (vs. 6% previously reported [36]), 25% in HER2 positive BC group (vs. 16% [36]) and 50% in TNBC group (vs. 20% [36]).